Share on LinkedInShare on LinkedIn

ARTICLE · 18 SEPTEMBER 2023

Federal Trade Commission Warns Against Improper Orange Book Listings

As announced in a September 14, 2023, press release, the FTC has issued a policy statement "warning pharmaceutical companies that make and sell brand-name...

United StatesIntellectual Property

As announced in a September 14, 2023, press release, the FTC has issued a policy statement "warning pharmaceutical companies that make and sell brand-name drugs that they could face legal action if they improperly list patents in the FDA's [Orange Book]." The policy statement builds on the premise that "[b]rand drug manufacturers may be harming generic competition through the improper listing of patents" in the Orange Book, and warns that the "FTC intends to use its full legal authority to protect patients and payors ... from business practices that tend to negatively affect competitive conditions," including "taking actions against companies and individuals that improperly list patents in the Orange Book that do not meet the statutory listing criteria."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from